Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion - A matched-pairs analysis

Ophthalmologica

Volumn 224, Issue 2, 2010, Pages 126-132

  Guthoff, Rainer ^a   Meigen, Thomas ^a   Hennemann, Kathrin ^a   Schrader, Wolfgang ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Maximilians Hospital Nürnberg   (Germany)

Author keywords

Avastin; Bevacizumab; Central retinal vein occlusion; Macular edema; Optical coherence tomography; Triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETATE;

ADULT; AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; NEOVASCULAR GLAUCOMA; RETINA DETACHMENT; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 69749127759     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235995     Document Type: Article

References (28)

1. Gutman FA, Zegarra H: Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984; 28(suppl):462-470.
2. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-1433.
3. Noma H, Funatsu H, Mimura T, Harino S, Hori S: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009; 116: 87-93.
4. Mohamed Q, McIntosh RL, Saw SM, Wong TY: Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114: 507-519, 524. (Pubitemid 46282974)
5. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E: Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247-248.
6. Cekic O, Chang S, Tseng JJ, Barile GR, Weissman H, Del Priore LV, Schiff WM, Weiss M, Klancnik JM Jr: Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005; 25: 846-850. (Pubitemid 41456574)
7. Gewaily D, Greenberg PB: Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009; 1: CD007324.
8. Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA: Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122: 1131-1136.
9. Goff MJ, Jumper JM, Yang SS, Fu AD, Johnson RN, McDonald HR, Ai E: Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina 2006; 26: 896-901.
10. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW Jr, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006; 26: 889-895.
11. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341: 309-315.
12. Sivaprasad S, McCluskey P, Lightman S: Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006; 84: 722-733.
13. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U: Intravitreal avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008; 92: 518-522.
14. Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Samuel MA, Vander JF, Regillo CD, Ho AC: Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007; 27: 1013-1019.
15. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A: Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007; 27: 1004-1012.
16. Ferrara DC, Koizumi H, Spaide RF: Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144: 864-871. (Pubitemid 350122344)
17. Stahl A, Agostini H, Hansen LL, Feltgen N: Bevacizumab in retinal vein occlusion - results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1429-1436.
18. Beutel J, Ziemssen F, Luke M, Partsch M, Bartz-Schmidt KU, Gelisken F: Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol 2008, Epub ahead of print.
19. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth UM: Intravitreal bevacizumab (Avastin- ) for macular edema secondary to retinal vein occlusion - twelvemonth results of a prospective clinical trial. Br J Ophthalmol 2008, Epub ahead of print.
20. Pournaras JA, Nguyen C, Vaudaux JD, Konstantinidis L, Ambresin A, Wolfensberger T: Treatment of central retinal vein occlusionrelated macular edema with intravitreal bevacizumab (Avastin): preliminary results. Klin Monatsbl Augenheilkd 2008; 225: 397-400.
21. Rensch F, Jonas JB, Spandau UH: Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008; 87: 77-81.
22. Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M, Wedrich A: Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2005; 83: 71-75. (Pubitemid 40326425)
23. Moschos MM, Moschos M: Intraocular bevacizumab for macular edema due to CRVO: a multifocal-ERG and OCT study. Doc Ophthalmol 2008; 116: 147-152.
24. Gelston CD, Olson JL, Mandava N: Macular oedema in central retinal vein occlusion treated with intravitreal triamcinolone. Acta Ophthalmol Scand 2006; 84: 314-318.
25. Wu WC, Cheng KC, Wu HJ: Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009, Epub ahead of print.
26. Ozdek SC, Aydin B, Gurelik G, Bahceci U, Hasanreisoglu B: Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion. Int Ophthalmol 2005; 26: 27-34.
27. Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
28. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBEVO study. Retina 2007; 27: 141-149.